14 thg 9, 2026•3 phút đọc
South Korea Introduces New Designation for Semi‑Innovative Pharma Firms with R&D‑Based Price Benefits
Korea's Ministry of Health and Welfare unveils a designation system granting generic price incentives to semi‑innovative pharma companies that meet R&D investment thresholds, excluding violations older than five years.